GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Change In Working Capital

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Change In Working Capital : HK$0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Change In Working Capital?

SciClone Pharmaceuticals (Holdings)'s change in working capital for the quarter that ended in Dec. 2023 was HK$0 Mil.

SciClone Pharmaceuticals (Holdings)'s change in working capital for the fiscal year that ended in Dec. 2023 was HK$-99 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

SciClone Pharmaceuticals (Holdings) Change In Working Capital Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Change In Working Capital Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Working Capital
Get a 7-Day Free Trial 365.60 -3.39 -57.34 -261.48 -98.55

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

SciClone Pharmaceuticals (Holdings) Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciClone Pharmaceuticals (Holdings) Change In Working Capital Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Change In Working Capital
Comparable Companies
HKSE:00460 HKSE:02877 HKSE:01558 HKSE:01349 HKSE:01681 HKSE:03613 HKSE:06896 HKSE:02348 HKSE:01061 HKSE:02552 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
Website
https://www.sciclone.com
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines